NO20050186L - Oligosakkaridbiomarkorer for mucopolysakkaridoser og andre beslektede forstyrrelser - Google Patents

Oligosakkaridbiomarkorer for mucopolysakkaridoser og andre beslektede forstyrrelser

Info

Publication number
NO20050186L
NO20050186L NO20050186A NO20050186A NO20050186L NO 20050186 L NO20050186 L NO 20050186L NO 20050186 A NO20050186 A NO 20050186A NO 20050186 A NO20050186 A NO 20050186A NO 20050186 L NO20050186 L NO 20050186L
Authority
NO
Norway
Prior art keywords
mps
oligosaccharide
target
solution
kit
Prior art date
Application number
NO20050186A
Other languages
English (en)
Other versions
NO20050186D0 (no
Inventor
Peter John Meikle
Maria Fuller
Steve Lewis Ramsey
Enzo Ranieri
John Joseph Hopwood
Original Assignee
Womens & Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Womens & Childrens Hospital filed Critical Womens & Childrens Hospital
Publication of NO20050186D0 publication Critical patent/NO20050186D0/no
Publication of NO20050186L publication Critical patent/NO20050186L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

Foreliggende oppfinnelse vedrører fremgangsmåter for diagnostisering av mukopolysakkaridose ("MPS") og beslektede sykdommer. Denne oppfinnelsen vedrører fremgangsmåter for identifisering og kvantifisering av biokjemiske markører (biomarkører) som er til stede i biologiske væsker eller vev fra en pasient som har en MPS eller en beslektet forstyrrelse. Ett aspekt av fremgangsmåten omfatter bestemmelse av en målmengde av et mål-MPS-biomarkøroligosakkarid fra en biologisk målprøve tatt fra måldyret og deretter sammenligne rnålmengden med en referansemengde fra et referanse-MPS-biomarkøroligosakkarid for diagnostiseringen, karakteriseringen og overvåkningen av den kliniske behandlingen av MPS og beslektede sykdommer. Denne oppfinnelsen beskriver også et sett som omfatter en oligosakkaridderivatiseringsløsning, en syreløsning, en intem standard, en fastfaseekstraheringskolonne, en fastfaseekstraheringskolonne-vaskeløsning, en oligosakkaridelueringsløsning og et sett med instruksjoner som veileder i anvendelse av settet for å diagnostisere en MPS eller en beslektet sykdom.
NO20050186A 2002-06-14 2005-01-13 Oligosakkaridbiomarkorer for mucopolysakkaridoser og andre beslektede forstyrrelser NO20050186L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPS2930A AUPS293002A0 (en) 2002-06-14 2002-06-14 Identification of oligosaccharides and their use in the diagnosis and evaluation of mucopolysaccharidoses and other related disorders
PCT/AU2003/000731 WO2003106997A1 (en) 2002-06-14 2003-06-13 Oligosaccharide biomarkers for mucopolysaccharidoses and other related disorders

Publications (2)

Publication Number Publication Date
NO20050186D0 NO20050186D0 (no) 2005-01-13
NO20050186L true NO20050186L (no) 2005-03-10

Family

ID=3836492

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050186A NO20050186L (no) 2002-06-14 2005-01-13 Oligosakkaridbiomarkorer for mucopolysakkaridoser og andre beslektede forstyrrelser

Country Status (11)

Country Link
US (1) US20060286034A1 (no)
EP (2) EP1532438B1 (no)
JP (1) JP2005530157A (no)
AT (1) ATE467834T1 (no)
AU (2) AUPS293002A0 (no)
CA (1) CA2488811A1 (no)
DE (1) DE60332538D1 (no)
NO (1) NO20050186L (no)
NZ (1) NZ537512A (no)
TW (1) TW200400351A (no)
WO (1) WO2003106997A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7951545B2 (en) 2002-04-30 2011-05-31 Seikagaku Corporation Method for detecting lysosomal storage diseases
CA2524272A1 (en) 2003-03-31 2004-10-14 Women's And Children's Hospital Multiplex screening for lysosomal storage disorders (lsds)
US20070134666A1 (en) * 2003-10-27 2007-06-14 Hiroshi Kasai Simultneous analytical method for oxidatively damaged guanine compound and concentration correcting substance thereof, and analyzer used for this analytical method
JP2006047239A (ja) * 2004-08-09 2006-02-16 National Institute Of Advanced Industrial & Technology 硫酸化単糖の同定方法及び硫酸化単糖異性体混合物の分析方法
US20070161074A1 (en) * 2005-12-27 2007-07-12 Daiichi Pharmaceutical Co., Ltd. Diagnostic method of mucopolysaccharidoses
CA2711590C (en) 2008-01-18 2021-03-23 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
JP2009229426A (ja) * 2008-03-25 2009-10-08 Sumitomo Bakelite Co Ltd 糖鎖分析法
CN102138069A (zh) * 2008-07-23 2011-07-27 P设备有限公司 便携式基于等离子体的诊断设备和诊断方法
US8592140B2 (en) 2009-01-02 2013-11-26 Biomarin Pharmaceutical Inc. Detection of oligosaccharides
US9029530B2 (en) * 2009-01-02 2015-05-12 Biomarin Pharmaceutical Inc. Detection of oligosaccharides
US8809009B2 (en) 2009-01-02 2014-08-19 Biomarin Pharmaceutical Inc. Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker
US8232073B2 (en) * 2009-01-02 2012-07-31 Zacharon Pharmaceuticals, Inc. Quantification of non-reducing end glycan residual compounds
US20130121984A1 (en) * 2011-11-07 2013-05-16 Shire Human Genetic Therapies, Inc. Biomarkers for sanfilippo syndrome and uses thereof
US9982288B2 (en) * 2014-04-30 2018-05-29 The Nemours Foundation Mucopolysaccharidosis IVA/VII screening and treatment method
MA40954A (fr) * 2014-11-14 2017-09-19 Shire Human Genetic Therapies Détermination de niveaux de glycosaminoglycane par spectrométrie de masse
CN107941963A (zh) * 2017-12-29 2018-04-20 珍奥集团股份有限公司 一种增加骨密度保健食品中盐酸氨基葡萄糖与硫酸软骨素的含量测定方法
CN116124971A (zh) * 2018-08-07 2023-05-16 江苏双林海洋生物药业有限公司 农产品中氨基葡萄糖含量的检测方法
CN108872441B (zh) * 2018-08-14 2021-09-03 江苏康缘药业股份有限公司 一种测定氨基葡萄糖和硫酸软骨素的方法
CN109781997A (zh) * 2019-01-22 2019-05-21 中国人民解放军总医院 用于诊断粘多糖病ⅱ型的生物标志物及其应用
CN114264741B (zh) * 2021-12-15 2022-08-19 山东大学 一种鉴别猪来源肝素是否掺反刍类动物肝素的方法
IT202200007808A1 (it) 2022-04-20 2023-10-20 Luigi Michele Pavone Composizioni terapeutiche per malattie causate da accumulo di eparan solfato
CN115032377B (zh) * 2022-08-11 2022-11-01 裕菁科技(上海)有限公司 一种粘多糖贮积症生物标记物及应用
CN117304367B (zh) * 2023-11-07 2025-12-12 中国海洋大学 岩藻糖化硫酸软骨素寡糖的衍生物及其制备方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310646A (en) * 1988-05-13 1994-05-10 Regents Of The University Of Minnesota Method for the detection of mucopolysaccharide storage diseases
US5310464A (en) 1991-01-04 1994-05-10 Redepenning Jody G Electrocrystallization of strongly adherent brushite coatings on prosthetic alloys
US6506384B1 (en) * 1997-12-31 2003-01-14 New York University Early detection of mycobacterial disease
NZ337946A (en) * 1998-09-25 2001-11-30 Tokyo Gas Co Ltd C-13 labelled oligosaccharides and polysaccharides useful as diagnostic agents for pancreatic exocrine function
RU2196988C2 (ru) * 2000-04-19 2003-01-20 Государственный новосибирский областной клинический диагностический центр Способ диагностики мукополисахаридозов
BR0111473A (pt) * 2000-06-07 2004-01-13 Univ Duke Métodos para triar um indivìduo quanto a uma doença de armazenagem de glicogênio, para triar um indivìduo quanto à doença de pompe, para monitorar a condição clìnica de um indivìduo com doença de pompe, para estimar a eficácia de um regime terapêutico em um indivìduo com doença de pompe e para determinar a concentração de um oligossacarìdeo em uma amostra biológica
GB0128498D0 (en) * 2001-11-28 2002-01-23 Inst Of Child Health International standards for sphingolipids

Also Published As

Publication number Publication date
EP1532438A1 (en) 2005-05-25
ATE467834T1 (de) 2010-05-15
US20060286034A1 (en) 2006-12-21
AU2003233255A1 (en) 2003-12-31
EP2081023A2 (en) 2009-07-22
EP2081023A3 (en) 2009-10-07
EP1532438B1 (en) 2010-05-12
AU2003233255C1 (en) 2009-07-16
WO2003106997A1 (en) 2003-12-24
NO20050186D0 (no) 2005-01-13
AUPS293002A0 (en) 2002-07-04
NZ537512A (en) 2006-09-29
AU2003233255B2 (en) 2009-02-19
EP1532438A4 (en) 2006-12-06
CA2488811A1 (en) 2003-12-24
DE60332538D1 (de) 2010-06-24
TW200400351A (en) 2004-01-01
JP2005530157A (ja) 2005-10-06

Similar Documents

Publication Publication Date Title
NO20050186L (no) Oligosakkaridbiomarkorer for mucopolysakkaridoser og andre beslektede forstyrrelser
US12104209B2 (en) Non-invasive diagnostic of non-alcoholic steatohepatitis
EP1922325A4 (en) METHODS FOR DIAGNOSING DEMENTIA AND OTHER NEUROLOGICAL DISORDERS
AU4469300A (en) Nmr-method for determining the risk of developing type 2 diabetes
WO2004046729A3 (en) Bodily fluid markers of tissue hypoxia
EP2770328A3 (en) Method to diagnose pancreatic cancer
KR102185987B1 (ko) Ripk3을 포함하는 당뇨병성 신증 진단용 바이오마커 및 이의 용도
US20090011452A1 (en) Method of Prognosis of Mental Diseases, E.G. Autism and Cerebral Palsy
JP5410955B2 (ja) ジペプチジルペプチダーゼ関連の疾患状態の診断および予後
RU2008103988A (ru) Способ диагностики рассеяного склероза
WO2005071407A3 (en) Methods of diagnosing acute coronary syndrome by measuring urotensin ii
ATE314648T1 (de) Diagnostisches verfahren für asthma
JP2009537797A (ja) 神経変性疾患の診断及び早期診断のためのｉｎｖｉｔｒｏ方法
WO2007015113A3 (en) New protein isoforms of the pif-family and uses thereof
WO2008125681A8 (en) Means and methods for assessing the risk of a cardiac intervention in patients suffering from a stable coronary heart disease based on gdf-15
TWI735470B (zh) 糖尿病性腎病之判定方法、及於此種判定方法中生物標記之用途
DE102008022609B4 (de) Verfahren zum Nachweis des Vorkommens von Nierensteinen und/oder Entzündungen der ableitenden Harnwege
JP6592637B1 (ja) Ｎａｆｌｄ又はｎａｓｈの検出又はリスクの予測方法、ｎａｆｌｄ又はｎａｓｈを検出するための診断薬キット、対象における肝線維化の進行度の判定方法、及び対象における肝線維化の進行度を判定するための診断薬キット
JP2020034537A (ja) Ｎａｆｌｄ又はｎａｓｈの検出又はリスクの予測方法、ｎａｆｌｄ又はｎａｓｈを検出するための診断薬キット、対象における肝線維化の進行度の判定方法、及び対象における肝線維化の進行度を判定するための診断薬キット
RU2015133019A (ru) Способ прогнозирования риска развития рака или диагностирования рака у индивидуума
DE602005023973D1 (de) Verfahren zur diagnose von chronischem stress und verwandten erkrankungen
JP4464298B2 (ja) 尿中のｎ２，ｎ２−ジメチルグアノシン濃度測定による心疾患の診断方法
Haddad et al. The Critical Role of Biochemical Markers in the Early Diagnosis of Chronic Diseases
Lee et al. Altered electrolyte and creatinine measurement with add-on testing on vitros 5600 and 5, 1 systems when using micro-container cups with pierceable caps
BR112018004372B1 (pt) Métodos in vitro para o diagnóstico da esteato-hepatite não alcoólica, método in vitro para classificar um indivíduo e método in vitro para calcular uma contagem de nash

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application